Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide


  1. 1. AACE/ADA Consensus Statement AMERICAN AssOCIATION Of ClINICAl ENDOCRINOlOgIsTs AND AMERICAN DIAbETEs AssOCIATION CONsENsUs sTATEMENT ON INPATIENT glYCEMIC CONTROl Etie S. Moghissi, MD, FACP, FACE1; Mary T. Korytkowski, MD2; Monica DiNardo, MSN, CRNP, CDE3; Daniel Einhorn, MD, FACP, FACE4; Richard Hellman, MD, FACP, FACE5; Irl B. Hirsch, MD6; Silvio E. Inzucchi, MD7; Faramarz Ismail-Beigi, MD, PhD8; M. Sue Kirkman, MD9; Guillermo E. Umpierrez, MD, FACP, FACE10 INTRODUCTION Abbreviations: AACE = American Association of Clinical People with diabetes are more likely to be hospitalized Endocrinologists; ACE = American College and to have longer durations of hospital stay than those of Endocrinology; ADA = American Diabetes without diabetes. A recent survey estimated that 22% of all Association; AMI = acute myocardial infarction; BG hospital inpatient days were incurred by people with diabe- = blood glucose; DIGAMI = Diabetes and Insulin- tes and that hospital inpatient care accounted for half of the Glucose Infusion in Acute Myocardial Infarction; ICUs $174 billion total US medical expenditures for this disease = intensive care units; IV = intravenous; LOS = length (1). These findings are due, in part, to the continued expan- of stay; NICE-SUGAR = Normoglycemia in Intensive sion of the worldwide epidemic of type 2 diabetes. In the Care Evaluation—Survival Using Glucose Algorithm United States alone, there are approximately 1.6 million Regulation; POC = point-of-care; RCTs = randomized new cases of diabetes each year, with an overall prevalence controlled trials; SSI = sliding scale insulin of 23.6 million people (7.8% of the population, with one- fourth of the cases remaining undiagnosed). An additional 57 million American adults are at high risk for type 2 dia- betes (2). Although the costs of illness-related stress hyper- glycemia are not known, they are likely to be considerable in light of the poor prognosis of such patients (3-6). This report is being published concurrently in 2009 in Endocrine Practice and There is substantial observational evidence linking Diabetes Care by the American Association of Clinical Endocrinologists and the American Diabetes Association. hyperglycemia in hospitalized patients (with or without From the 1Department of Medicine, University of California Los Angeles, Los diabetes) to poor outcomes. Cohort studies as well as a few Angeles, California, 2Department of Medicine, Division of Endocrinology early randomized controlled trials (RCTs) suggested that and Metabolism, University of Pittsburgh, Pittsburgh, Pennsylvania, 3Division of Endocrinology and Metabolism, Veterans Affairs Pittsburgh intensive treatment of hyperglycemia improved hospital Health Center and University of Pittsburgh School of Nursing PhD outcomes (5-8). In 2004, this evidence led the American Program, Pittsburgh, Pennsylvania, 4Scripps Whittier Diabetes Institute, College of Endocrinology (ACE) and the American La Jolla, California, University of California San Diego School of Medicine, San Diego, California, and Diabetes and Endocrine Associates, La Jolla, Association of Clinical Endocrinologists (AACE), in col- California, 5Department of Medicine, University of Missouri-Kansas City laboration with the American Diabetes Association (ADA) School of Medicine and Hellman and Rosen Endocrine Associates, North and other medical organizations, to develop recommen- Kansas City, Missouri, 6Department of Medicine, University of Washington School of Medicine, Seattle, Washington, 7Department of Medicine, dations for treatment of inpatient hyperglycemia (9). In Section of Endocrinology, Yale University School of Medicine and the Yale 2005, the ADA added recommendations for treatment of Diabetes Center, Yale-New Haven Hospital, New Haven, Connecticut, 8Department of Medicine, Physiology and Biophysics, Division of Clinical hyperglycemia in the hospital to its annual Standards of and Molecular Endocrinology, Case Western Reserve University, Cleveland, Medical Care (10). Recommendations from ACE and ADA Ohio, 9Clinical Affairs, American Diabetes Association, Alexandria, Virginia, generally endorsed tight glycemic control in critical care and 10Department of Medicine/Endocrinology, Emory University, Atlanta, units. For patients in general medical and surgical units, Georgia. Address correspondence and reprint requests to Dr. Etie S. Moghissi, 4644 where RCT evidence regarding treatment targets was lack- Lincoln Boulevard, Suite 409, Marina del Rey, CA 90292. ing, glycemic goals similar to those advised for outpatients © 2009 by the American Association of Clinical Endocrinologists and the were advocated (9,10). In 2006, ACE and ADA partnered American Diabetes Association. on a joint “Call to Action” for inpatient glycemic control, ENDOCRINE PRACTICE Vol 15 No. 4 May/June 2009 1
  2. 2. 2 Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4) addressing a number of systematic implementation barriers Intervention directed at reducing blood glucose (BG) in hospitals (11). These efforts contributed to a growing levels has resulted in improved outcomes in some, but not national movement viewing the management of inpatient all, studies (5,18-25). Several recent clinical trials in criti- hyperglycemia as a quality-of-care measure. cally ill patients have reported no reduction in mortality Although hyperglycemia is associated with adverse from intensive treatment targeting near-euglycemia versus patient outcomes, intervention to normalize glycemia conventional management targeting BG <180 mg/dL (<10.0 has yielded inconsistent results. Indeed, recent trials mmol/L). Of considerable concern are reports of harm, with in critically ill patients have failed to show a significant higher rates of severe hypoglycemia and even increased improvement in mortality with intensive glycemic control mortality (14) resulting from intensive glycemic control (12,13) or have even shown increased mortality risk (14). (12-14,16,27,28). This variability in results may be attribut- Moreover, these recent RCTs have highlighted the risk of able to several factors, including differences in intravenous severe hypoglycemia resulting from such efforts (12-17). (IV) insulin treatment protocols and their implementation, These outcomes have contributed to confusion regarding glycemic targets, patient populations, methods for glucose specific glycemic targets and the means for achieving them monitoring, and insulin adjustment (12,29). in both critically ill and noncritically ill patients. The following section focuses primarily on results of Recognizing the importance of glycemic control across recent studies with RCT design that investigated patient the continuum of care, AACE and ADA joined forces to outcomes with protocols targeting near-normalization of develop this updated consensus statement on inpatient BG levels. Readers are referred to a previous ACE position glycemic management. The central goals were to identify statement (9), an ACE/ADA consensus statement (11), and reasonable, achievable, and safe glycemic targets and to a technical review (8) for details related to earlier studies describe the protocols, procedures, and system improve- supporting inpatient glycemic management. ments needed to facilitate their implementation. This docu- ment is addressed to health care professionals, support- Data Derived From Surgical and ing staff, hospital administrators, and other stakeholders Medical Intensive Care Units focused on improved management of hyperglycemia in Observational studies have documented that hyper- inpatient settings. Consensus panel members extensively glycemia after cardiothoracic surgical procedures is asso- reviewed the most current literature and considered the fol- ciated with higher rates (approximately 2-fold) of wound lowing questions: infection (20,30). Interventions to reduce hyperglycemia in this setting with IV insulin therapy decrease infection rates 1. Does improving glycemic control improve clinical (19,21,31) and cardiac-related mortality (5,32), in compar- outcomes for inpatients with hyperglycemia? ison with historical control subjects. 2. What glycemic targets can be recommended in differ- The results of several RCTs conducted in critically ent patient populations? ill patients in medical and surgical intensive care units 3. What treatment options are available for achieving (ICUs) are summarized in Table 1 (5,13,14,16,27,28,33- optimal glycemic targets safely and effectively in spe- 36). Intensive insulin therapy targeting arterial glucose cific clinical situations? levels of 80 to 110 mg/dL (4.4 to 6.1 mmol/L) in a primar- 4. Does inpatient management of hyperglycemia repre- ily surgical ICU patient population resulted in a significant sent a safety concern? decrease in morbidity and mortality (5). However, imple- 5. What systems need to be in place to achieve these mentation of the identical protocol in 1,200 medical ICU recommendations? patients by the same investigators in the same institution 6. Is treatment of inpatient hyperglycemia cost- effective? diminished morbidity but failed to reduce mortality. A 6- 7. What are the optimal strategies for transition to outpa- fold increase in severe hypoglycemic events (BG <40 mg/ tient care? dL [2.2 mmol/L]) was observed in the intensively treated 8. What are areas for future research? group (18.7% versus 3.1%), and hypoglycemia was identi- fied as an independent risk factor for mortality (16). QUESTION 1: Does improving glycemic control The Efficacy of Volume Substitution and Insulin improve clinical outcomes for inpatients with Therapy in Severe Sepsis (VISEP) study reported no hyperglycemia? decrease in mortality and higher rates of severe hypoglyce- mia with intensive insulin therapy in patients with severe Hyperglycemia in hospitalized patients, irrespective sepsis (17% versus 4.1%; P<.001) (13). Hypoglycemia— of its cause, is unequivocally associated with adverse out- BG <40 mg/dL (<2.2 mmol/L)—was identified as an comes (5,6,18-25). Hyperglycemia occurs in patients with independent risk factor for mortality (relative risk, 2.2 at known or undiagnosed diabetes, or it occurs during acute 28 days; 95% confidence interval, 1.6 to 3.0) (Dr. Frank illness in those with previously normal glucose tolerance Brunkhorst, personal communication, 2009). Similarly, (termed “stress hyperglycemia”) (8,26). intensive glycemic control in a mixed medical and surgi-
  3. 3. Table 1 Summary Data of Selected Randomized Controlled Trials of Intensive Insulin Therapy in Critically Ill Patients (>200 Randomized Patients)a Blood glucose target, Blood glucose achieved,b Odds mg/dL (mmol/L) mg/dL (mmol/L) Primary End point rate ratioc Trial N Setting Intensive Conventional Intensive Conventional outcome Intensive Conventional ARRc RRRc (95% CI) DIGAMI (33), 1995 620 CCU 126-196 Usual care 173 211 1-year 18.6% 26.1% 7.5% 29%d NR (AMI) (7-10.9) (9.6) (11.7) mortality Van den Berghe et al 1,548 SICU 80-110 180-200 103 153 ICU 4.6% 8.0% 3.4% 42% 0.58d (5), 2001 (4.4-6.1) (10-11) (5.7) (8.5) mortality (0.38-0.78) DIGAMI 2 (34), 2005 1,253 CCU 126-180 Usual care 164 180 2-year Group 1, Group 3, …e …e NR (AMI) (7-10) (group 3) (9.1) (10) mortality 23.4%; 17.9% (groups 1 group 2, & 2) 21.2% Van den Berghe et al 1,200 MICU 80-110 180-200 111 153 Hospital 37.3% 40.0% 2.7% 7.0% 0.94e (16), 2006 (4.4-6.1) (10-11) (6.2) (8.5) mortality (0.84-1.06) HI-5 (35), 2006 240 CCU 72-180 Usual care 149 162 6-month 7.9% 6.1% −1.8%e −30%e NR (AMI) (4-10) <288 (8.3) (9) mortality (GIK) (<16) GluControlf (27), 2007 1,101 ICU 80-110 140-180 118 144 ICU 16.7% 15.2% −1.5% −10% 1.10e (4.4-6.1) (7.8-10) (6.5) (8) mortality (0.84-1.44) Gandhi et al (36), 2007 399 Operating 80-110 <200 114 157 Compositeg 44% 46% 2% 4.3% 1.0e room (4.4-6.1) (<11) (6.3) (8.7) (0.8-1.2) VISEP (13), 2008 537h ICU 80-110 180-200 112 151 28-day 24.7% 26.0% 1.3% 5.0% 0.89e,i (4.4-6.1) (10-11) (6.2) (8.4) mortality (0.58-1.38) De La Rosa et alf (28), 504 SICU 80-110 180-200 117 148 28-day 36.6% 32.4% −4.2%e −13%e NR 2008 MICU (4.4-6.1) (10-11) (6.5) (8.2) mortality NICE-SUGAR (14), 6,104 ICU 81-108 ≤180 115 145 3-month 27.5% 24.9% −2.6% −10.6% 1.14d 2009 (4.5-6) (≤10) (6.4) (8.0) mortality (1.02-1.28) a AMI = acute myocardial infarction; ARR = absolute risk reduction; CCU = coronary care unit; CI = confidence interval; GIK = glucose-insulin-potassium; ICU = intensive care units (mixed); MICU = medical intensive care unit(s); NR = not reported; RRR = relative risk reduction; SICU = surgical intensive care unit. b Mean morning blood glucose concentrations (except for GluControl, which reported mean overall blood glucose concentrations). c Intensive group versus conventional group. d P<.05. e Not significant (P>.05). f Presented as abstract only. g Composite of death, sternal infection, prolonged ventilation, cardiac arrhythmias, stroke, and renal failure at 30 days. h Only patients with sepsis. i Personal communications, Dr. Frank Brunkhorst. Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4)
  4. 4. 4 Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4) cal ICU resulted in no decrease in morbidity or mortality, Several studies have attempted to reproduce the favor- while increasing the rate of hypoglycemia 5-fold (28). able outcomes observed with early implementation of insu- The largest study to date, Normoglycemia in Intensive lin therapy reported in the first Diabetes and Insulin-Glucose Care Evaluation—Survival Using Glucose Algorithm Infusion in Acute Myocardial Infarction (DIGAMI) trial Regulation (NICE-SUGAR), a multicenter, multinational (33). DIGAMI 2, a multicenter RCT of 1,253 patients RCT, tested the effect of tight glycemic control on out- with AMI and diabetes, failed to show a decrease in mor- comes among 6,104 critically ill participants, the major- tality with such intervention (34). The Hyperglycemia ity of whom (95%) required mechanical ventilation (14). Intensive Insulin Infusion in Infarction (HI-5) study ran- The 90-day mortality was significantly higher in the inten- domly assigned patients with AMI to 24-hour infusions of sively treated versus the conventionally treated group (78 insulin plus glucose for 24 hours (BG goal 180 mg/dL more deaths; 27.5% versus 24.9%; P = .02) in both sur- [10.0 mmol/L]) or usual care. There were no significant gical and medical patients. Mortality from cardiovascular differences in mortality, although there was a decreased causes was more common in the intensively treated group incidence of congestive heart failure and reinfarction at (76 more deaths; 41.6% versus 35.8%; P = .02). Severe 3 months in the intensively treated group (35). The very hypoglycemia was also more common in the intensively large Clinical Trial of Reviparin and Metabolic Modulation treated group (6.8% versus 0.5%; P.001). in Acute Myocardial Infarction Treatment Evaluation— A recent meta-analysis of RCTs reported compari- Estudios Cardiologicos Latin America (CREATE-ECLA), sons between intensive insulin therapy with glycemic tar- with 20,201 patients, tested the efficacy of glucose-insu- gets of 72 to 126 mg/dL (4.0 to 7.0 mmol/L) (commonly, lin-potassium infusion in post-AMI patients and found no 80 to 110 mg/dL [4.4 to 6.1 mmol/L]) and less intensive decrease in mortality (44). A failure to achieve a prespeci- therapy with targets of 150 to 220 mg/dL (8.3 to 12.2 fied glycemic target with intensive therapy that differed mmol/L) (commonly, 180 to 200 mg/dL [10.0 to 11.1 from those in the control group may have contributed to mmol/L]). Among 8,432 critically ill patients, there was these negative results (34,44). no significant difference in mortality between intensive therapy and control groups (21.6% versus 23.3%, respec- Data Derived From Other Critically Ill Patients tively) (12). A decrease in septicemia and a 5-fold increase Several retrospective studies have examined the in hypoglycemia (13.7% versus 2.5%) were observed. In relationship between glycemia and clinical outcomes in a second meta-analysis (17) including 13,567 critically ill patients with extensive burns, body trauma, or traumatic patients, a favorable effect of intensive therapy on mortal- brain injury or those who have undergone surgical treat- ity was noted only in surgical ICU patients (relative risk, ment for cerebral aneurysms (45-53). In patients with 0.63; confidence interval, 0.44 to 0.91). There was a 6-fold subarachnoid hemorrhage, hyperglycemia was associated increase in the rate of occurrence of hypoglycemia with with impaired cognition and deficits in gross neurologic use of intensive therapy in all ICU patients (17). function at 3 months (52). Patients without diabetes who The higher rates of severe hypoglycemia associated had severe blunt injury and hyperglycemia (BG 200 with intensive insulin therapy (12-14,16,27,28) raise the mg/dL [11.1 mmol/L]) were found to have a 2.2-fold possibility that serious adverse events in the subgroup higher rate of mortality than those with admission glucose of patients experiencing hypoglycemia offset, at least in of less than 200 mg/dL (11.1 mmol/L) (54). Similar find- part, any benefit derived from strict glycemic control in ings have been reported by some investigators (55,56) but the much larger subgroup of patients without hypoglyce- not others (57,58). In an RCT of tight glycemic control mic events (13,16). Hypoglycemic events, however, have in 97 patients with severe traumatic brain injury (59), no been infrequently linked to mortality; this finding suggests significant differences were noted in infections, 6-month that severe hypoglycemia may be a marker of more serious mortality, or neurologic outcomes. The rate of occurrence underlying disease (13,14,16). of hypoglycemia was 2-fold higher with use of intensive insulin therapy. Data Derived From Patients With Acute Myocardial Infarction Data Derived From Patients Although hyperglycemia is associated with adverse Undergoing Transplantation outcomes after acute myocardial infarction (AMI) (37- Diabetes in patients after transplant procedures shares 41), reduction of glycemia per se, and not necessarily the many similarities with type 2 diabetes and is strongly asso- use of insulin, is associated with improved outcomes (7). ciated with cardiovascular disease and cardiac death (60). It remains unclear, however, whether hyperglycemia is Fuji et al (61) examined the effects of hyperglycemia dur- a marker of underlying health status or is a mediator of ing neutropenic periods in 112 patients undergoing stem complications after AMI. Non-iatrogenic hypoglycemia cell transplantation. Hyperglycemia was associated with has also been associated with adverse outcomes and is a risk of organ failure, grade II to IV acute graft-versus-host predictor of higher mortality (7,42,43). disease, and non-relapse-related mortality, but not with
  5. 5. Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4) 5 infection or fever. A similar study in 382 patients reported nantly surgical ICU population (5), this target has been diffi- that in those patients not treated with glucocorticoids during cult to achieve in subsequent studies, including the recently neutropenia, each 10 mg/dL (0.6 mmol/L) increase in BG published NICE-SUGAR study (14), without increasing was associated with a 1.15-fold increase in the odds ratio the risk for severe hypoglycemia (12,13,16,27,28). In addi- for bacteremia (62). Hammer et al (63) analyzed BG lev- tion, there has been no consistent reduction in mortality els among 1,175 adult patients receiving allogeneic hema- with intensive control of glycemia (12,17), and increased topoietic cell transplants. Hyperglycemia, hypoglycemia, mortality was observed in the largest published study to and glycemic variability all correlated with non-relapse- date (14). The reasons for this inconsistency are not entirely related mortality within 200 days after transplantation. clear. The positive results reported in the initial studies may have been attributable to differences in measurement and Data Derived From Studies on Intraoperative reporting of BG values, selection of participants, glycemic Glycemic Management variability, or nutritional support (12,17,84). Nevertheless, In a double-blind, placebo-controlled RCT involving recent attempts to achieve tight glycemic control either 82 adults, intraoperative glucose-insulin-potassium infu- have not reduced or have actually increased mortality in sion during a coronary artery bypass grafting procedure multicenter trials and clearly led to higher rates of hypo- did not reduce myocardial damage, mortality, or length of glycemia (13,14,16). stay (LOS) (64). In a study of 399 patients undergoing car- Despite the inconsistencies, it would be a serious error diac surgical procedures, intensive insulin therapy (target to conclude that judicious control of glycemia in critically BG, 80 to 100 mg/dL [4.4 to 5.6 mmol/L]) intraoperatively ill patients, and in non-ICU patients in general, is not war- resulted in no difference in patient outcomes; postopera- ranted. First, on the basis of a large number of studies in tively, however, both groups were treated to similar glyce- a variety of inpatient settings, uncontrolled hyperglycemia mic targets (36). clearly is associated with poor outcomes. Second, although severe hypoglycemic events are observed in an unaccept- Data Derived From Pediatric ICUs ably high number of patients receiving intensive insulin Although outside the scope of this consensus statement, therapy with protocols targeting a BG of 80 to 110 mg/dL it is worth noting that hyperglycemia (without diabetes) is (4.4 to 6.1 mmol/L) (12), this risk can likely be minimized also common among pediatric patients with critical illness with relaxation of targets, improvement and standardization (65-70), and it correlates with mortality (70). An interna- of protocols, and their careful implementation. Third, per- tional, multicenter RCT, which tested the effect of inten- haps major beneficial effects on outcomes can be derived sive glycemic control in very-low-birth-weight neonates, from a higher target range of glucose than 80 to 110 mg/dL found higher rates of severe hypoglycemia and no signifi- in comparison with uncontrolled hyperglycemia. cant difference in mortality or morbidity (71). In contrast, Finally, until further information becomes available, another randomized trial conducted among 700 critically ill it is prudent to continue to emphasize the importance of infants (n = 317) and children (n = 383) reported decreases glycemic control in hospitalized patients with critical and in mortality, inflammatory markers, and LOS with use of noncritical illness while aiming at targets that are less strin- intensive insulin therapy, despite a greater frequency of gent than 80 to 110 mg/dL (4.4 to 6.1 mmol/L), a topic that severe hypoglycemia (25% versus 5%) (72). is discussed in detail subsequently. Hyperglycemia in Hospitalized Medical and QUESTION 2: What glycemic targets can be Surgical Patients in Non-ICU Settings recommended in different patient populations? No RCTs have examined the effect of intensive gly- cemic control on outcomes in hospitalized patients outside The management of hyperglycemia in the hospital ICU settings. Several observational studies, however, point presents unique challenges that stem from variations in a to a strong association between hyperglycemia and poor clinical outcomes, including prolonged hospital stay, infec- patient’s nutritional status and level of consciousness, the tion, disability after discharge from the hospital, and death practical limitations of intermittent glycemic monitoring, (4,7,35,73-81). and the ultimate importance of patient safety. Accordingly, Several studies have found glucose variability to be an reasonable glucose targets in the hospital setting are mod- independent predictor of mortality in critically ill patients estly higher than may be routinely advised for patients with (63,66,82). Whether intervention to control glycemic vari- diabetes in the outpatient setting (85,86). ability, per se, improves outcomes is not known (83). Definition of Glucose Abnormalities Summary of the Clinical Trials In this report, hyperglycemia is defined as any BG Reviewed for Question 1 value 140 mg/dL (7.8 mmol/L). Levels that are signifi- Overall, although a very tight glucose target (80 to 110 cantly and persistently above this level may necessitate mg/dL [4.4 to 6.1 mmol/L]) was beneficial in a predomi- treatment in hospitalized patients. In patients without a
  6. 6. Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4) previous diagnosis of diabetes, elevated BG concentra- the aforementioned cut points. In contrast, higher glucose tions may be due to stress hyperglycemia, a condition that ranges may be acceptable in terminally ill patients or in can be established by a review of prior medical records or patients with severe comorbidities, as well as in those in measurement of hemoglobin A1c. Hemoglobin A1c values patient-care settings where frequent glucose monitoring or of 6.5% to 7.0% suggest that diabetes preceded hospital- close nursing supervision is not feasible. ization (87). We emphasize that clinical judgment in combination Hypoglycemia is defined as any BG level 70 mg/dL with ongoing assessment of the patient’s clinical status, (3.9 mmol/L) (88). This is the standard definition in outpa- including changes in the trajectory of glucose measures, tients and correlates with the initial threshold for the release the severity of illness, the nutritional status, or the concur- of counterregulatory hormones (89). Severe hypoglycemia rent use of medications that might affect glucose levels (for in hospitalized patients has been defined by many clinicians example, corticosteroids or octreotide), must be incorpo- as 40 mg/dL (2.2 mmol/L), although this value is lower rated into the day-to-day decisions regarding insulin dos- than the approximate 50 mg/dL (2.8 mmol/L) level at which ing (93,94). cognitive impairment begins in normal persons (89-91). As with hyperglycemia, hypoglycemia among inpatients is Inpatient Glucose Metrics also associated with adverse short-term and long-term out- Hospitals attempting to improve the quality of their comes. Early recognition and treatment of mild to moder- glycemic control and clinical investigators who analyze ate hypoglycemia (40 and 69 mg/dL [2.2 and 3.8 mmol/L], glycemic management require standardized glucose mea- respectively) can prevent deterioration to a more severe epi- sures for assessment of baseline performance and the effect sode with potential adverse sequelae (91,92). of any intervention (11). Several methods have been pro- posed for determining the adequacy of glycemic control Treatment of Hyperglycemia in across a hospital or unit. A recent study indicated that a Critically Ill Patients simple measure of mean BG (39) provides information On the basis of the available evidence, insulin infusion similar to that from more complex metrics (hyperglycemic should be used to control hyperglycemia in the majority index, time-averaged glucose) (14,48). The “patient-day” of critically ill patients in the ICU setting, with a starting unit of measure is another proposed metric of hospital glu- threshold of no higher than 180 mg/dL (10.0 mmol/L). cose data, especially when there is substantial variability in Once IV insulin therapy has been initiated, the glucose the duration of hospital stay (95). The patient-day metric level should be maintained between 140 and 180 mg/dL may yield a more accurate assessment of the frequency of (7.8 and 10.0 mmol/L), and greater benefit may be realized hypoglycemia and severe hyperglycemic events, provid- at the lower end of this range. Although strong evidence is ing an approach for obtaining measures of performance for lacking, somewhat lower glucose targets may be appropri- clinical investigation (95). ate in selected patients. Targets less than 110 mg/dL (6.1 The absolute definition of high-quality BG control has mmol/L), however, are not recommended. Use of insulin not been determined. Of course, one should aim for the infusion protocols with demonstrated safety and efficacy, highest percentage of patients within a prespecified BG tar- resulting in low rates of occurrence of hypoglycemia, is get range. The opposite holds true for hypoglycemia. What highly recommended. is reasonable for a hospital to achieve and with what con- sistency have not been studied, and information regarding Treatment of Hyperglycemia in best practices in this area is needed. Noncritically Ill Patients With no prospective, RCT data for establishing spe- QUESTION 3: What treatment options are cific guidelines in noncritically ill patients, our recommen- available for achieving optimal glycemic targets dations are based on clinical experience and judgment. For safely and effectively in specific clinical situations? the majority of noncritically ill patients treated with insu- lin, premeal glucose targets should generally be 140 mg/ In the hospital setting, insulin therapy is the preferred dL (7.8 mmol/L) in conjunction with random BG values method for achieving glycemic control in most clinical 180 mg/dL (10.0 mmol/L), as long as these targets can situations (8). In the ICU, IV infusion is the preferred route be safely achieved. For avoidance of hypoglycemia, con- of insulin administration. Outside of critical care units, sideration should be given to reassessing the insulin regi- subcutaneous administration of insulin is used much more men if BG levels decline below 100 mg/dL (5.6 mmol/L). frequently. Orally administered agents have a limited role Modification of the regimen is necessary when BG values in the inpatient setting. are 70 mg/dL (3.9 mmol/L), unless the event is easily explained by other factors (such as a missed meal). Intravenous Insulin Infusions Occasional clinically stable patients with a prior his- In the critical care setting, continuous IV insulin infu- tory of successful tight glycemic control in the outpatient sion has been shown to be the most effective method for setting may be maintained with a glucose range below achieving specific glycemic targets (8). Because of the
  7. 7. Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4) very short half-life of circulating insulin, IV delivery Injectable noninsulin therapies such as exenatide and allows rapid dosing adjustments to address alterations in pramlintide have limitations similar to those with orally the status of patients. administered agents in the hospital setting. IV insulin therapy is ideally administered by means of validated written or computerized protocols that allow for Specific Clinical Situations predefined adjustments in the insulin infusion rate based Patients Using an Insulin Pump on glycemic fluctuations and insulin dose. An extensive Patients who use continuous subcutaneous insulin review of the merits and deficiencies of published proto- infusion (pump) therapy in the outpatient setting can be cols is beyond the intent of this statement, and readers are candidates for diabetes self-management in the hospital, referred to several available reports and reviews (96-101). provided they have the mental and physical capacity to Continued education of staff in conjunction with periodic do so (8,103,114,115). Of importance, nursing personnel ongoing review of patient data is critical for successful must document basal rates and bolus doses on a regular implementation of any insulin protocol (97-101). basis (at least daily). The availability of hospital personnel Patients who receive IV insulin infusions will usually with expertise in continuous subcutaneous insulin infusion require transition to subcutaneously administered insulin therapy is essential (115). when they begin eating regular meals or are transferred to lower intensity care. Typically, a percentage (usually 75% Patients Receiving Enteral Nutrition to 80%) of the total daily IV infusion dose is proportionately Hyperglycemia is a common side effect of inpatient divided into basal and prandial components (see subse- enteral nutrition therapy (116,117). A recent study, in quent material). Importantly, subcutaneously administered which a combination of basal insulin and correction insu- insulin must be given 1 to 4 hours before discontinuation of lin was used, achieved a mean glucose value of 160 mg/dL IV insulin therapy in order to prevent hyperglycemia (102). (8.9 mmol/L). Similar results were achieved in the group Despite these recommendations, a safe and effective transi- randomized to receive SSI only; however, 48% of patients tion regimen has not been substantiated. required the addition of intermediate-acting insulin to achieve glycemic targets (109). Subcutaneously Administered Insulin Scheduled subcutaneous administration of insulin is Patients Receiving Parenteral Nutrition the preferred method for achieving and maintaining glu- The high glucose load in standard parenteral nutrition cose control in non-ICU patients with diabetes or stress frequently results in hyperglycemia, which is associated hyperglycemia. The recommended components of inpa- with a higher incidence of complications and mortality in tient subcutaneous insulin regimens are a basal, a nutri- critically ill patients in the ICU (118). Insulin therapy is tional, and a supplemental (correction) element (8,103). highly recommended, with glucose targets as defined pre- Each component can be met by one of several available viously on the basis of the severity of illness. insulin products, depending on the particular hospital situ- ation. Readers are referred to several recent publications Patients Receiving Glucocorticoid Therapy and reviews that describe currently available insulin prepa- Hyperglycemia is a common complication of cor- rations and protocols (101-106). ticosteroid therapy (93). Several approaches have been A topic that deserves particular attention is the per- proposed for treatment of this condition, but no published sistent overuse of what has been branded as sliding scale protocols or studies have investigated the efficacy of these insulin (SSI) for management of hyperglycemia. The term approaches. A reasonable approach is to institute glucose “correction insulin,” which refers to the use of additional monitoring for at least 48 hours in all patients receiving short- or rapid-acting insulin in conjunction with scheduled high-dose glucocorticoid therapy and to initiate insulin insulin doses to treat BG levels above desired targets, is therapy as appropriate (94). In patients who are already preferred (8). Prolonged therapy with SSI as the sole regi- being treated for hyperglycemia, early adjustment of insu- men is ineffective in the majority of patients (and poten- lin doses is recommended (119). Importantly, during cor- tially dangerous in those with type 1 diabetes) (106-112). ticosteroid tapers, insulin dosing should be proactively adjusted to avoid hypoglycemia. Noninsulin Agents Noninsulin agents are inappropriate in most hospital- QUESTION 4: Does inpatient management of ized patients. Continued use of such agents may be appro- hyperglycemia represent a safety concern? priate in selected stable patients who are expected to con- sume meals at regular intervals. Caution must be exercised Overtreatment and undertreatment of hyperglycemia with use of metformin because of the potential develop- represent major safety issues in hospitalized patients with ment of a contraindication during the hospitalization, such and without diabetes (90,120,121). Fear of hypoglycemia, as renal insufficiency, unstable hemodynamic status, or clinical inertia, and medical errors are major barriers to need for imaging studies with radiocontrast dye (8,113). achieving optimal blood glucose control (90,122-131).
  8. 8. Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4) In most clinical situations, safe and reasonable glycemic Blood Glucose Monitoring control can be achieved with appropriate use of insulin, Bedside BG monitoring with use of point-of-care adjusted according to results of bedside glucose monitor- (POC) glucose meters is performed before meals and at ing (102,106,109). bedtime in most inpatients who are eating usual meals. It Clinical situations that increase the risk for hypo- is important to avoid routine use of correction insulin at glycemia and hyperglycemia in the hospital include the bedtime. In patients who are receiving continuous enteral following: or parenteral nutrition, glucose monitoring is optimally performed every 4 to 6 hours. In patients who are receiv- 1. Changes in caloric or carbohydrate intake (“nothing ing cycled enteral nutrition or parenteral nutrition, the by mouth” status, enteral nutrition, or parenteral nutri- schedule for glucose monitoring can be individualized but tion) (94,128) should be frequent enough to detect hyperglycemia during 2. Change in clinical status or medications (for example, feedings and the risk of hypoglycemia when feedings are corticosteroids or vasopressors) (93,98) interrupted (109,112). More frequent BG testing, ranging 3. Failure of the clinician to make adjustments to glyce- from every 30 minutes to every 2 hours, is required for mic therapy based on daily BG patterns (102,128) patients receiving IV insulin infusions. 4. Prolonged use of SSI as monotherapy (107,108) 5. Poor coordination of BG testing and administration of Glucose Meters insulin with meals (121,129) Safe and rational glycemic management relies on the 6. Poor communication during times of patient transfer accuracy of BG measurements performed with use of POC to different care teams (120,121) glucose meters, which have several important limitations. 7. Use of long-acting sulfonylureas in elderly patients Although the US Food and Drug Administration allows a and those with kidney or liver insufficiency ±20% error for glucose meters, questions have been raised 8. Errors in order writing and transcription (102,120) about the appropriateness of this criterion (138). Glucose measurements differ significantly between plasma and Hypoglycemia is a major safety concern with use whole blood, terms that are often used interchangeably and of insulin and insulin secretagogues. Hypoglycemia can can lead to misinterpretation. Most commercially available occur spontaneously in patients with sepsis (130) or in capillary glucose meters introduce a correction factor of patients who receive certain medications, including quin- approximately 1.12 to report a “plasma adjusted” value olone antibiotics and β-adrenergic agonists. Although not (139). all hypoglycemic episodes are avoidable, the use of nurse- Significant discrepancies among capillary, venous, driven hypoglycemia treatment protocols that prompt early and arterial plasma samples have been observed in patients therapy for any BG levels 70 mg/dL (3.9 mmol/L) can with low or high hemoglobin concentrations, hypoperfu- prevent deterioration of potentially mild events—for exam- sion, or the presence of interfering substances (139,140). ple, BG values of 60 to 69 mg/dL (3.3 to 3.8 mmol/L)—to Analytical variability has been described with several POC more severe events—for example, BG concentrations 40 glucose meters (141). Any glucose result that does not cor- mg/dL (2.2 mmol/L) (90-92,98,131). Particular attention relate with the patient’s clinical status should be confirmed is required in high-risk patients, including those with mal- through conventional laboratory sampling of plasma nutrition; advanced age; a history of severe hypoglycemia (88,132); or autonomic, kidney, liver, or cardiac failure. glucose. Clinical inertia can be defined as not adjusting glyce- Although laboratory measurement of plasma glucose mic therapy in response to persistently abnormal results has less variability and interference, multiple daily phle- on BG determination (123). Often, there is a lack of own- botomies are not practical. Moreover, the use of indwelling ership for diabetes management, particularly in hospital- lines as the sampling source poses risks for infection. Studies ized patients admitted with a primary diagnosis other than performed with use of continuous interstitial glucose moni- diabetes (128). This inaction may be due in part to insuf- toring systems in the critical care setting (142,143) currently ficient knowledge or confidence in diabetes management are limited by the lack of reliability of BG measurements in (123,133). Improvements in care can be achieved by ongo- the hypoglycemic range as well as by cost. ing education and training (134,135). QUESTION 5: What systems need to be in place to Insulin Errors achieve these recommendations? Insulin has consistently been designated as a high-alert medication because of the risk of harm that can accom- The complexity of inpatient glycemic management pany errors in prescribing, transcribing, or dosing (136). necessitates a systems approach that facilitates safe prac- The true frequency of such errors is unknown because the tices and reduces the risk for errors (120,121). Systems that available data sources depend on voluntary reporting of facilitate the appropriate use of scheduled insulin therapy, errors (102,137) and mechanisms for real-time root-cause with institutional support for inpatient personnel who are analysis are not available in most hospitals. knowledgeable in glycemic management, are essential for
  9. 9. Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4) 9 achieving safe and reasonable levels of glycemic control to an increase in time needed from physicians, nurses, phar- in hospitalized patients. Readers are referred to the 2006 macists, and other services. These costs are best viewed as ACE/ADA consensus statement, which outlines the sys- short-term investments that ultimately provide long-term tems that must be in place to promote effective glycemic cost savings because of improved clinical outcomes, with management in the hospital (11). Some of these recommen- observed decreases in LOS, inpatient complications, and dations are reviewed briefly in the following paragraphs. need for rehospitalization (148-155). The success of any glycemic management program Pharmacoeconomic analyses have examined the cost- depends on the ability to obtain financial support from effectiveness of improved glycemic control in the hospital hospital administrators, who should be made aware of the setting (148,149). In the Portland Diabetic Project, a 17- potential for cost savings with reductions in morbidity, year prospective nonrandomized study of 4,864 patients durations of hospital stay, and need for readmission. This with diabetes who underwent open heart surgical pro- support is necessary for covering the costs of staff edu- cedures, institution of continuous IV insulin therapy to cation, equipment, and personnel to oversee an inpatient achieve predetermined target BG levels reduced the inci- diabetes management program (144). dence of deep sternal wound infections by 66%, resulting The creation of a multidisciplinary steering committee in a total net savings to the hospital of $4,638 per patient guided by local diabetes experts can establish reasonable (148). In another study, intensive glycemic control in 1,600 and achievable glycemic management goals with use of patients treated in a medical ICU was associated with a protocols and order sets (90). Preprinted order sets or com- total cost savings of $1,580 per patient (149). Van den puterized ordering systems with adequate technical sup- Berghe et al (150) reported cost savings of $3,476 (US dol- port are useful tools for facilitating appropriate glycemic lars) per patient by strict normalization of BG levels with therapy (8,11,145). These tools can advance orders that use of a post hoc health care resource utilization analysis contain contingencies that promote patient safety, such as of their randomized mechanically ventilated surgical ICU withholding prandial insulin if a patient will not eat (102). patients. In a retrospective analysis of patients undergoing Protocols need to be reviewed periodically and revised in coronary artery bypass grafting, each 50 mg/dL (2.8 mmol/ accordance with available evidence. L) increase in BG values on the day of and after the surgi- Inpatient providers often have insufficient knowledge cal procedure was associated with an increase in hospital about the many aspects of inpatient diabetes care (133). cost of $1,769 and an increase in duration of hospital stay Thus, education of personnel is essential, especially early of 0.76 day (151). In a tertiary care trauma center, imple- during the implementation phase (101,127). Formal com- mentation of a diabetes management program to reduce the munication among various disciplines and services helps monthly mean BG level by 26 mg/dL (1.4 mmol/L) (177 to garner support from hospital personnel for new practices mg/dL to 151 mg/dL [9.8 to 8.4 mmol/L]) resulted in sig- and protocols, as well as providing a venue for identifying nificant reductions in LOS (0.26 day) in association with concerns. estimated hospital savings of more than $2 million per year Many hospitals are challenged by poor coordination (152). In another study, implementation of a subcutaneous of meal delivery and prandial insulin administration (130), insulin protocol for treatment of patients with hyperglyce- as well as variability in the carbohydrate content of meals mia in the emergency department resulted in a subsequent (94). Ensuring appropriate administration of insulin with reduction of hospital stay by 1.5 days (153). respect to meals despite variations in food delivery neces- The use of an intensified inpatient protocol by a diabe- sitates coordination between dietary and nursing services tes management team resulted in correct coding and treat- (122). A systems approach can also promote the coordi- ment of patients with previously unrecognized hyperglyce- nation of glucose monitoring, insulin administration, and mia. The LOS was reduced for both primary and secondary meal delivery, particularly during change of shifts and diagnoses of diabetes, and readmission rates declined (154). times of patient transfer (121,122). In a different study, the use of diabetes team consultation Electronic health records and computerized physi- resulted in a 56% reduction in LOS and a cost reduction of cian order entry systems have the potential to improve the $2,353 per patient (155). sharing of information, including POC glucose results and Thus, intensive glycemic control programs have associated medication administration—which can contrib- reported substantial cost savings, primarily attributable ute to the reduction of medical errors. These systems can to decreases in laboratory, pharmacy, and radiology costs; also provide access to algorithms, protocols, and decision fewer inpatient complications; decreased ventilator days; support tools that can help guide therapy (146,147). and reductions in ICU and hospital LOS. These reports demonstrate that optimization of inpa- QUESTION 6: Is treatment of inpatient tient glycemic management not only is effective in reduc- hyperglycemia cost-effective? ing morbidity and mortality but also is cost-effective. The business case for hospital support of glycemic manage- A program of inpatient glycemic control with prespeci- ment programs is based on opportunities for improving the fied glycemic targets will have associated costs attributable accuracy of documentation and coding for diabetes-related
  10. 10. 10 Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4) diagnoses. The case for revenue generation through billing Medication errors and adverse drug events have been for clinical services is based on opportunities to increase linked to poor communication of instructions to the patient the provision of glycemic management services in the at the time of discharge (156,157). This is particularly true hospital. It is imperative to involve hospital administra- for insulin regimens, which are inherently more complex. tion in providing the necessary financial support for inpa- Because the day of discharge is not always conducive tient glycemic management programs that will ultimately to retention of verbal instructions (158), clearly written result in cost savings in conjunction with improved patient instructions provide a reference for patients and their out- outcomes. patient providers, and they provide a format for medication reconciliation between inpatient and outpatient settings. In QUESTION 7: What are the optimal strategies for one recent study, an insulin-specific discharge instruction transition to outpatient care? form provided greater clarity and more consistent direc- tions for insulin dosing and self-testing of BG in compari- Preparation for transition to the outpatient setting is son with a generic hospital discharge form (159). an important goal of inpatient diabetes management and An outpatient follow-up visit with the primary care begins with the hospital admission. This entails a funda- provider, endocrinologist, or diabetes educator within 1 mental shift in responsibility from a situation in which hos- month after discharge from the hospital is advised for all pital personnel provide the diabetes care to one in which the patients having hyperglycemia in the hospital (8). Clear patient is capable of self-management. Successful coordi- communication with outpatient providers either directly nation of this transition requires a team approach that may or by means of hospital discharge summaries facilitates involve physicians, nurses, medical assistants, dietitians, safe transitions to outpatient care. Providing information case-managers, and social workers (8). Hospitals with cer- regarding the cause or the plan for determining the cause of tified diabetes educators benefit from their expertise during hyperglycemia, related complications and comorbidities, the discharge process. and recommended treatments can assist outpatient provid- Admission assessment obtains information regarding ers as they assume ongoing care. any prior history of diabetes or hyperglycemia, its man- agement, and the level of glycemic control. Early assess- QUESTION 8: What are areas for future research? ment of a patient’s cognitive abilities, literacy level, visual acuity, dexterity, cultural context, and financial resources The following are selected research topics and ques- for acquiring outpatient diabetic supplies allows sufficient tions proposed for guiding the management of patients time to prepare the patient and address problem areas. with hyperglycemia in various hospital settings. Hospitalization provides a unique opportunity for addressing a patient’s education in diabetes self-manage- Stress Hyperglycemia ment (3). Because the mean hospital LOS is usually less • What are the underlying mechanisms? than 5 days (2) and the capacity to learn new material may • What abnormalities lead to variability in insulin resis- be limited during acute illness, diabetes-related education tance observed in some critically ill patients? is frequently limited to an inventory of basic “survival • What therapeutic modalities, in addition to glyce- skills.” mic control, would improve outcomes in critically ill It is recommended that the following areas be reviewed patients with hyperglycemia? and addressed before the patient is discharged from the • Are there optimal and safe glycemic targets specific to hospital (8): certain populations of critically ill patients? • Level of understanding related to the diagnosis of Severe Hypoglycemia diabetes • What is the profile of inpatients at greatest risk for • Self-monitoring of BG and explanation of home BG severe hypoglycemia? goals • What are the short-term and long-term outcomes of • Definition, recognition, treatment, and prevention of patients experiencing severe hypoglycemia? hyperglycemia and hypoglycemia • What are the true costs of inpatient hypoglycemia? • Identification of health care provider who will be responsible for diabetes care after discharge Glycemic Targets on General Medical • Information on consistent eating patterns and Surgical Wards • When and how to take BG-lowering medications, • What are optimal and safe glycemic targets in non- including administration of insulin (if the patient is critically ill patients on medical and surgical wards? receiving insulin for ongoing management at home) Recommended end points for an RCT include rates of • Sick-day management hypoglycemia, hospital-acquired infections, other in- • Proper use and disposal of needles and syringes hospital complications, LOS, and readmission.
  11. 11. Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4) 11 Glycemic Variability Insulin Treatment and Monitoring Instruments • What is the effect of glycemic variability and the rate • What are safe and effective strategies for inpatient use of change in glycemia on short-term and long-term out- of insulin and insulin analogues? comes, both in ICU and non-ICU settings? • What is the role of continuous glucose monitoring sys- tems in inpatient settings? Hospital Systems and Safety • What hospital systems and safety measures are important for improving glycemic control and patient outcomes? Pediatric Inpatient Populations • What teams and support systems are required for safe and • What are the optimal and safe glycemic targets in non- effective transition of patients to the outpatient setting? critically ill hospitalized children? SUMMARY OF RECOMMENDATIONS I. Critically Ill Patients • Clinical judgment and ongoing assessment of clinical • Insulin therapy should be initiated for treatment of status must be incorporated into day-to-day decisions persistent hyperglycemia, starting at a threshold of no regarding treatment of hyperglycemia. greater than 180 mg/dL (10.0 mmol/L). • Once insulin therapy has been started, a glucose range III. Safety Issues of 140 to 180 mg/dL (7.8 to 10.0 mmol/L) is recom- • Overtreatment and undertreatment of hyperglycemia mended for the majority of critically ill patients. represent major safety concerns. • Intravenous insulin infusions are the preferred method • Education of hospital personnel is essential in engag- for achieving and maintaining glycemic control in ing the support of those involved in the care of inpa- critically ill patients. tients with hyperglycemia. • Validated insulin infusion protocols with demonstrated • Caution is required in interpreting results of POC glu- safety and efficacy, and with low rates of occurrence cose meters in patients with anemia, polycythemia, of hypoglycemia, are recommended. hypoperfusion, or use of some medications. • With IV insulin therapy, frequent glucose monitoring • Buy-in and financial support from hospital adminis- is essential to minimize the occurrence of hypoglyce- tration are required for promoting a rational systems mia and to achieve optimal glucose control. approach to inpatient glycemic management. II. Noncritically Ill Patients • For the majority of noncritically ill patients treated IV. Cost with insulin, the premeal BG target should generally • Appropriate inpatient management of hyperglycemia be 140 mg/dL (7.8 mmol/L) in conjunction with is cost-effective. random BG values 180 mg/dL (10.0 mmol/L), pro- vided these targets can be safely achieved. • More stringent targets may be appropriate in stable V. Discharge Planning patients with previous tight glycemic control. • Preparation for transition to the outpatient setting • Less stringent targets may be appropriate in terminally should begin at the time of hospital admission. ill patients or in patients with severe comorbidities. • Discharge planning, patient education, and clear com- • Scheduled subcutaneous administration of insulin, munication with outpatient providers are critical for with basal, nutritional, and correction components, is ensuring a safe and successful transition to outpatient the preferred method for achieving and maintaining glycemic management. glucose control. • Prolonged therapy with SSI as the sole regimen is VI. Needed Research discouraged. • A selected number of research questions and topics for • Noninsulin antihyperglycemic agents are not appropri- guiding the management of inpatient hyperglycemia ate in most hospitalized patients who require therapy in various hospital settings are proposed. for hyperglycemia.
  12. 12. 12 Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4) ACKNOWLEDGMENT 4. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker We acknowledge the medical writing assistance of of in-hospital mortality in patients with undiagnosed diabe- Kate Mann, PharmD. tes. J Clin Endocrinol Metab. 2002;87:978-982. 5. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001; DISCLOSURE 345:1359-1367. 6. Malmberg K, Norhammar A, Wedel H, et al. Ms. Monica DiNardo reports that she has received Glycometabolic state at admission: important risk marker consultant fees from sanofi-aventis U.S. LLC. of mortality in conventionally treated patients with dia- Dr. Daniel Einhorn reports that he has received con- betes mellitus and acute myocardial infarction; long-term sultant fees from Merck Co., Inc., consultant fees and results from the Diabetes and Insulin-Glucose Infusion in research grant support from Amylin Pharmaceuticals, Inc., Acute Myocardial Infarction (DIGAMI) study. Circulation. sanofi-aventis U.S. LLC, and Takeda Pharmaceuticals 1999;99:2626-2632. North America, Inc., and research grant support from 7. Kosiborod M, Inzucchi SE, Goyal A, et al. The relation- AstraZeneca 2009, GlaxoSmithKline, Johnson Johnson ship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial Services, Inc., Eli Lilly Company, Medtronic, Inc., and infarction [abstract]. Circulation. 2008;118(suppl):S1109. Novo Nordisk A/S and is a stockholder with Halozyme 8. Clement S, Braithwaite SS, Magee MF (American Therapeutics and MannKind Corporation. Diabetes Association Diabetes in Hospitals Writing Dr. Richard Hellman reports that he has no relevant Committee). Management of diabetes and hyperglycemia conflicts of interest. in hospitals [published corrections appear in Diabetes Care. Dr. Irl B. Hirsch reports that he has received consul- 2004;27:856 and Diabetes Care. 2004;27:1255]. Diabetes tant fees from Abbott Laboratories, F. Hoffman La Roche Care. 2004;27:553-591. Ltd. (Roche), Johnson Johnson Services, Inc., and Novo 9. Garber AJ, Moghissi ES, Bransome ED Jr, et al Nordisk A/S. (American College of Endocrinology Task Force on Dr. Silvio E. Inzucchi reports that he has received Inpatient Diabetes and Metabolic Control). American research grant support from Eli Lilly Company. College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr Pract. 2004;10: Dr. Faramarz Ismail-Beigi reports that he has no rel- 77-82. evant conflicts of interest. 10. American Diabetes Association. Standards of medical care Dr. M. Sue Kirkman reports that she has no relevant in diabetes [published correction appears in Diabetes Care. conflicts of interest. 2005;28:990]. Diabetes Care. 2005;28(suppl 1):S4-S36. Dr. Mary T. Korytkowski reports that she has received 11. ACE/ADA Task Force on Inpatient Diabetes. American consultant fees from Eli Lilly Company, Merck Co., College of Endocrinology and American Diabetes Inc., and Novo Nordisk A/S and research grant support Association consensus statement on inpatient diabetes and from sanofi-aventis U.S. LLC. glycemic control. Endocr Pract. 2006;12:458-468. Dr. Etie S. Moghissi reports that she has received 12. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of consultant fees from and is a stockholder with Amylin tight glucose control in critically ill adults: a meta-analy- Pharmaceuticals, Inc. and Novo Nordisk A/S. sis [published correction appears in JAMA. 2008;301:936]. JAMA. 2008;300:933-944. Dr. Guillermo E. Umpierrez reports that he has 13. Brunkhorst FM, Engel C, Bloos F, et al (German received consultant fees from Merck Co., Inc. and con- Competence Network Sepsis [SepNet]). Intensive insulin sultant fees and research grant support from sanofi-aventis therapy and pentastarch resuscitation in severe sepsis. N U.S. LLC. Engl J Med. 2008;358:125-139. 14. Finfer S, Chittock DR, Su SY, et al (NICE-SUGAR Study REFERENCES Investigators). Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360: 1. American Diabetes Association. Economic costs of dia- 1283-1297. betes in the U.S. in 2007 [published correction appears in 15. Krinsley JS, Grover A. Severe hypoglycemia in criti- Diabetes Care. 2008;31:1271]. Diabetes Care. 2008;31: cally ill patients: risk factors and outcomes. Crit Care Med. 596-615. 2007;35:2262-2267. 2. Centers for Disease Control and Prevention. National 16. Van den Berghe G, Wilmer A, Hermans G, et al. diabetes fact sheet: general information and national esti- Intensive insulin therapy in the medical ICU. N Engl J Med. mates on diabetes in the United States, 2007. Atlanta, GA: 2006;354:449-461. US Department of Health and Human Services, Centers for 17. Griesdale DE, de Souza RJ, van Dam RM, et al. Intensive Disease Control and Prevention, 2008. insulin therapy and mortality among critically ill patients: 3. Levetan CS, Passaro M, Jablonski K, Kass M, Ratner a meta-analysis including NICE-SUGAR study data [pub- RE. Unrecognized diabetes among hospitalized patients. lished online ahead of print March 24, 2009]. CMAJ. doi: Diabetes Care. 1998;21:246-249. 10.1503/cmaj.090206.
  13. 13. Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4) 1 18. Malmberg K (DIGAMI [Diabetes Mellitus, Insulin before and during the era of intensive glycemic manage- Glucose Infusion in Acute Myocardial Infarction] ment: six and one-half years experience at a university- Study Group). Prospective randomised study of intensive affiliated community hospital. Semin Thorac Cardiovasc insulin treatment on long term survival after acute myo- Surg. 2006;18:317-325. cardial infarction in patients with diabetes mellitus. BMJ. 33. Malmberg K, Rydén L, Efendic S, et al. Randomized 1997;314:1512-1515. trial of insulin-glucose infusion followed by subcutaneous 19. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. insulin treatment in diabetic patients with acute myocardial Continuous intravenous insulin infusion reduces the inci- infarction (DIGAMI study): effects on mortality at 1 year. J dence of deep sternal wound infection in diabetic patients Am Coll Cardiol. 1995;26:57-65. after cardiac surgical procedures [with discussion]. Ann 34. Malmberg K, Rydén L, Wedel H, et al (DIGAMI 2 Thorac Surg. 1999;67:352-362. Investigators). Intense metabolic control by means of insu- 20. Latham R, Lancaster AD, Covington JF, Pirolo JS, lin in patients with diabetes mellitus and acute myocardial Thomas CS. The association of diabetes and glucose control infarction (DIGAMI 2): effects on mortality and morbidity. with surgical site infections among cardiothoracic surgery Eur Heart J. 2005;26:650-661. patients. Infec Control Hosp Epidemiol. 2001;22:607-612. 35. Cheung NW, Wong VW, McLean M. The Hyperglycemia: 21. Sala J, Masiá R, González de Molina FJ, et al (REGICOR Intensive Insulin Infusion in Infarction (HI-5) study; a ran- Investigators). Short-term mortality of myocardial infarc- domized controlled trial of insulin infusion therapy for tion patients with diabetes or hyperglycaemia during admis- myocardial infarction. Diabetes Care. 2006;29:765-770. sion. J Epidemiol Community Health. 2002;56:707-712. 36. Gandhi GY, Nuttall GA, Abel MD, et al. Intensive intra- 22. Furnary AP, Gao G, Grunkemeier GL, et al. Continuous operative insulin therapy versus conventional glucose man- insulin infusion reduces mortality in patients with diabe- agement during cardiac surgery: a randomized trial. Ann tes undergoing coronary artery bypass grafting. J Thorac Intern Med. 2007;146:233-243. Cardiovasc Surg. 2003;125:1007-1021. 37. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress 23. Krinsley JS. Effect of intensive glucose management proto- hyperglycaemia and increased risk of death after myocar- col on the mortality of critically ill adult patients [published dial infarction in patients with and without diabetes: a sys- correction appears in Mayo Clin Proc. 2005;80:1101]. tematic overview. Lancet. 2000;355:773-778. Mayo Clin Proc. 2004;79:992-1000. 38. Kosiborod M, Rathore SS, Inzucchi SE, et al. Admission 24. Pittas AG, Siegel RD, Lau J. Insulin therapy for critically glucose and mortality in elderly patients hospitalized with ill hospitalized patients: a meta-analysis of randomized, acute myocardial infarction: implications for patients with controlled trials. Arch Intern Med. 2004;164:2005-2011. and without recognized diabetes. Circulation. 2005;111: 25. Ishihara M, Kojima S, Sakamoto T, et al (Japanese 3078-3086. Acute Coronary Syndrome Study Investigators). Acute 39. Kosiborod M, Inzucchi SE, Krumholz HM, et al. hyperglycemia is associated with adverse outcome after Glucometrics in patients hospitalized with acute myocar- acute myocardial infarction in the coronary intervention dial infarction: defining the optimal outcomes-based mea- era. Am Heart J. 2005;150:814-820. sure of risk. Circulation. 2008;117:1018-1027. 26. Mizock BA. Alterations in carbohydrate metabolism dur- 40. Goyal A, Mahaffey KW, Garg J, et al. Prognostic signifi- ing stress: a review of the literature. Am J Med. 1995;98: cance of the change in glucose level in the first 24 h after 75-84. acute myocardial infarction: results from the CARDINAL 27. Devos P, Preiser JC, Mélot C (GluControl Steering study. Eur Heart J. 2006;27:1289-1297. Committee). Impact of tight glucose control by intensive 41. Deedwania P, Kosiborod M, Barrett E, et al (American insulin therapy on ICU mortality and the rate of hypogly- Heart Association Diabetes Committee of the Council caemia: final results of the GluControl study [abstract]. on Nutrition, Physical Activity, and Metabolism). Intensive Care Med. 2007;33:S189. Hyperglycemia and acute coronary syndrome: a scientific 28. De La Rosa GD, Donado JH, Restrepo AH, et al (Grupo statement from the American Heart Association Diabetes de Investigacion en Cuidado Intensivo [GICIHPTU]). Committee of the Council on Nutrition, Physical Activity, Strict glycaemic control in patients hospitalised in a mixed and Metabolism. Circulation. 2008;117:1610-1619. medical and surgical intensive care unit: a randomised clin- 42. Pinto DS, Skolnick AH, Kirtane AJ, et al (TIMI Study ical trial. Crit Care. 2008;12:R120. Group). U-shaped relationship of blood glucose with adverse 29. Finfer S, Delaney A. Tight glycemic control in critically ill outcomes among patients with ST-segment elevation myo- adults. JAMA. 2008;300:963-965. cardial infarction. J Am Coll Cardiol. 2005;46:178-180. 30. Golden SH, Peart-Vigilance C, Kao WH, Brancati FL. 43. Svensson AM, McGuire DK, Abrahamsson P, Dellborg Perioperative glycemic conrol and the risk of infectious M. Association between hyper- and hypoglycaemia and 2 complications in a cohort of adults with diabetes. Diabetes year all-cause mortality risk in diabetic patients with acute Care. 1999;22:1408-1414. coronary events. Eur Heart J. 2005;26:1255-1261. 31. Zerr KJ, Furnary AP, Grunkemeier GL, Bookin S, 44. Mehta SR, Yusuf S, Diaz R, et al (CREATE-ECLA Trial Kanhere V, Starr A. Glucose control lowers the risk of Group Investigators). Effect of glucose-insulin-potassium wound infection in diabetics after open heart operations. infusion on mortality in patients with acute ST-segment Ann Thorac Surg. 1997;63:356-361. elevation myocardial infarction: the CREATE-ECLA ran- 32. Krinsley JS. Glycemic control, diabetic status, and mortal- domized controlled trial. JAMA. 2005;293:437-446. ity in a heterogeneous population of critically ill patients
  14. 14. 14 Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4) 45. Laird AM, Miller PR, Kilgo PD, Meredith JW, Chang 62. Derr RL, Hsiao VC, Saudek CD. Antecedent hypergly- MC. Relationship of early hyperglycemia to mortality in cemia is associated with an increased risk of neutropenic trauma patients. J Trauma. 2004;56:1058-1062. infections during bone marrow transplantation. Diabetes 46. Jeremitsky E, Omert LA, Dunham CM, Wilberger J, Care. 2008;31:1972-1977. Rodriguez A. The impact of hyperglycemia on patients 63. Hammer MJ, Casper C, Gooley TA, O’Donnell PV, with severe brain injury. J Trauma. 2005;58:47-50. Boeckh M, Hirsch IB. The contribution of malglycemia 47. Gale SC, Sicoutris C, Reilly PM, Schwab CW, Gracias to mortality among allogeneic hematopoietic cell trans- VH. Poor glycemic control is associated with increased plant recipients. Biol Blood Marrow Transplant. 2009;15: mortality in critically ill trauma patients. Am Surg. 2007;73: 344-351. 454-460. 64. Shim YH, Kweon TD, Lee JH, Nam SB, Kwak YL. 48. Vogelzang M, van der Horst ICC, Nijsten MW. Intravenous glucose-insulin-potassium during off-pump Hyperglycaemic index as a tool to assess glucose control: a coronary artery bypass surgery does not reduce myocardial retrospective study. Crit Care. 2004;8:R122- R127. injury. Acta Anaesthesiol Scand. 2006;50:954-961. 49. Duane TM, Ivatury RR, Dechert T, et al. Blood glucose 65. Wintergerst KA, Buckingham B, Gandrud L, Wong levels at 24 hours after trauma fails to predict outcomes. J BJ, Kachce S, Wilson DM. Association of hypoglycemia, Trauma. 2008;64:1184-1187. hyperglycemia, and glucose variability with morbidity and 50. Cochran A, Davis L, Morris SE, Saffle JR. Safety and death in the pediatric intensive care unit. Pediatrics. 2006; efficacy of an intensive insulin protocol in a burn-trauma 118:173-179. intensive care unit. J Burn Care Res. 2008;29:187-191. 66. Palacio A, Smiley D, Ceron M, et al. Prevalence and clini- 51. Wahl WL, Taddonio M, Maggio PM, Arbabi S, Hemmila cal outcome of inpatient hyperglycemia in a community MR. Mean glucose values predict trauma patient mortality. pediatric hospital. J Hosp Med. 2008;3:212-217. J Trauma. 2008;65:42-47. 52. Pasternak JJ, McGregor DG, Schroeder DR, et al 67. Faustino EV, Apkon M. Persistent hyperglycemia in criti- (IHAST Investigators). Hyperglycemia in patients under- cally ill children. J Pediatr. 2005;146:30-34. going cerebral aneurysm surgery: its association with long- 68. Branco RG, Garcia PC, Piva JP, Casartelli CH, Seibel V, term gross neurologic and neuropsychological function. Tasker RC. Glucose level and risk of mortality in pediatric Mayo Clin Proc. 2008;83:406-417. septic shock. Pediatr Crit Care Med. 2005;6:470-472. 53. Mowery NT, Gunter OL, Guillamondegui O, et al. Stress 69. Tuggle DW, Kuhn MA, Jones SK, Garza JJ, Skinner S. insulin resistance is a marker for mortality in traumatic brain Hyperglycemia and infections in pediatric trauma patients. injury [with discussion]. J Trauma. 2009;66:145-153. Am Surg. 2008;74:195-198. 54. Sung J, Bochicchio GV, Joshi M, Bochicchio K, Tracy 70. Falcao G, Ulate K, Kouzekanani K, Bielefeld MR, K, Scalea TM. Admission hyperglycemia is predictive Morales JM, Rotta AT. Impact of postoperative hyper- of outcome in critically ill trauma patients. J Trauma. glycemia following surgical repair of congenital cardiac 2005;59:80-83. defects. Pediatr Cardiol. 2008;29:628-636. 55. Bochicchio GV, Joshi M, Bochicchio KM, et al. Early 71. Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL, et hyperglycemic control is important in critically injured al. Early insulin therapy in very-low-birth-weight infants. trauma patients. J Trauma. 2007;63:1353-1358. N Engl J Med. 2008;359:1873-1884. 56. Yendamuri S, Fulda GJ, Tinkoff GH. Admission hyper- 72. Vlasselaers D, Milants I, Desmet L, et al. Intensive insu- glycemia as a prognostic indicator in trauma. J Trauma. lin therapy for patients in paediatric intensive care: a pro- 2003;55:33-38. spective, randomised controlled study. Lancet. 2009;373: 57. Collier B, Diaz J Jr, Forbes R, et al. The impact of a nor- 547-556. moglycemic management protocol on clinical outcomes in 73. Pomposelli JJ, Baxter JK III, Babineau TJ, et al. Early the trauma intensive care unit [with discussion]. JPEN J postoperative glucose control predicts nosocomial infec- Parenter Enteral Nutr. 2005;29:353-359. tion rate in diabetic patients. JPEN J Parenter Enteral Nutr. 58. Shin S, Britt RC, Reed SF, Collins J, Weireter LJ, 1998;22:77-81. Britt LD. Early glucose normalization does not improve 74. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein outcome in the critically ill trauma population. Am Surg. HC. Stress hyperglycemia and prognosis of stroke in nondi- 2007;73:769-772. abetic and diabetic patients: a systematic overview. Stroke. 59. Bilotta F, Caramia R, Cernak I, et al. Intensive insulin 2001;32:2426-2432. therapy after severe traumatic brain injury: a randomized 75. Bruno A, Gregori D, Caropreso A, Lazzarato F, Petrinco clinical trial. Neurocrit Care. 2008;9:159-166. M, Pagano E. Normal glucose values are associated with 60. Davidson JA, Wilkinson A (International Expert Panel a lower risk of mortality in hospitalized patients. Diabetes on New-Onset Diabetes After Transplantation). New- Care. 2008;31:2209-2210. Onset Diabetes After Transplantation 2003 International 76. Norhammar AM, Rydén L, Malmberg K. Admission Consensus Guidelines: an endocrinologist’s view. Diabetes plasma glucose: independent risk factor for long-term Care. 2004;27:805-812. prognosis after myocardial infarction even in nondiabetic 61. Fuji S, Kim SW, Mori S, et al. Hyperglycemia dur- patients. Diabetes Care. 1999;22:1827-1831. ing the neutropenic period is associated with a poor out- 77. Finney SJ, Zekveld C, Elia A, Evans TW. Glucose con- come in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation. Transplantation. trol and mortality in critically ill patients. JAMA. 2003;290: 2007;84:814-820. 2041-2047.